

ANNOUNCING THE FOURTEENTH ROUND OF APPLICATIONS TO THE GLOBAL DRUG FACILITY

The fourteenth round of applications to the Global Drug Facility (GDF) is now open and the secretariat is accepting applications from governments and non-governmental organizations for free grants of first line anti-tuberculosis drugs. The closing date for applications is **Monday, 2 October 2006**.

The application materials are available on the GDF website:

http://www.stoptb.org/gdf/applying/application_documents.asp

Completed forms should be submitted to the GDF (gdf@who.int) for consideration by its Technical Review Committee. Please refer to the application form and accompanying notes for information on eligibility requirements and the terms and conditions of GDF support.

We encourage you to submit completed applications and supporting documentation electronically. If an electronic submission is not possible, paper-based applications are acceptable.

The following products are currently available from the Global Drug Facility:

1. Cat I & III Patient Kit: Full treatment for a Cat I or Cat III patient in the following regimens:

Six (6) month

- 2(R150/H75/Z400/E275) / 4 (R150/H75)**
- 2(R150/H75/Z400/E275) / 4(R150/H150)₃

Eight (8) month

- 2(R150/H75/Z400/E275) / 6 (E400/H150)

2. Cat II Patient Kit: Full treatment for a Cat II patient for 8 months in the following regimens:

- 2S(R150/H75/Z400/E275)/1(R150/H75/Z400/E275) / 5 (R150/H75/E275)**
2S(R150/H75/Z400/E275)/1(R150/H75/Z400/E275) / 5 (R150/H75) E275

3. Rifampicin/Isoniazid/Pyrazinamide/Ethambutol (150/75/400/275 mg)
4. Rifampicin/Isoniazid/Ethambutol (150/75/275)
5. Rifampicin/Isoniazid (150/75 mg)
6. Rifampicin/Isoniazid (150/150 mg)
7. Ethambutol/Isoniazid (400/150 mg)
8. Pyrazinamide (400 mg)
9. Ethambutol (400 mg)
10. Isoniazid (300 mg)
11. Streptomycin Sulphate vials (1g) & water for injection (5ml vials)
12. Hypodermic syringes (standard and auto-disabling)

All of the above formulations (1-10) are available in blisters (28 tablets per blister/24 blisters per box) or loose (in jars of 1,000 tablets). Please visit the following website:

http://www.stoptb.org/gdf/drugsupply/drugs_available.asp for more details on these products.

GDF grant support is dependent on approval by the GDF Technical Review Committee and on the availability of resources.

Please send the application form to the following address:

**Global Drug Facility
Stop TB Partnership Secretariat
C/o World Health Organization
20, avenue Appia
CH-1211 Geneva 27
Switzerland
Fax: +41 22 791 4886/ +41 22 791 4497
Attention: Andrea Moreira
Email: gdf@who.int**